(Q47914426)

6 February 2018

title

Hypertension as a surrogate marker for the activity of anti-VEGF agents (English)

1 reference

6 February 2018

0 references

O Mir

1

1 reference

6 February 2018

S Ropert

series ordinal

2

1 reference

6 February 2018

J Alexandre

series ordinal

3

1 reference

6 February 2018

F Goldwasser

series ordinal

4

1 reference

6 February 2018

publication date

1 May 2009

1 reference

6 February 2018

published in

Annals of Oncology

1 reference

6 February 2018

volume

20

1 reference

6 February 2018

issue

5

1 reference

6 February 2018

page(s)

967-970

1 reference

6 February 2018

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP206

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP206

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP206

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP206

Mechanisms of hypertension associated with BAY 43-9006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP206

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP206

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP206

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP206

Quantifying hypertension in patients with cancer treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP206

2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP206

Home blood-pressure monitoring in patients receiving sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP206

Non-neoplastic renal diseases are often unrecognized in adult tumor nephrectomy specimens: a review of 246 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP206

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDP206

1 reference

6 February 2018

1 reference

6 February 2018